Vigonvita Life Sciences Co (HKSE:02630) EBIT: HK$ Mil (TTM As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

HKSE:02630 Vigonvita Life Sciences Co Ltd HKSE:02630
8 GF Score
Price HK$90.00
! 2 Warning Signs
View Full Analysis

What is Vigonvita Life Sciences Co EBIT?

Vigonvita Life Sciences Co HKSE:02630 +5.32% 8 EBIT is HK$ Mil as of Dec. 2025. GuruFocus rates HKSE:02630 with a GF Score™ of 8/100. The stock has 2 warning signs investors should review.

Vigonvita Life Sciences Co's earnings before interest and taxes (EBIT) for the six months ended in Dec. 2025 was HK$-379.5 Mil.

EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. Vigonvita Life Sciences Co's annualized ROC % for the quarter that ended in Dec. 2025 was -33.30%. Vigonvita Life Sciences Co's annualized ROC (Joel Greenblatt) % for the quarter that ended in Dec. 2025 was -72.95%.

EBIT is also linked to Joel Greenblatt's definition of earnings yield.

Vigonvita Life Sciences Co  (HKSE:02630) EBIT Explanation

1. EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

Vigonvita Life Sciences Co's annualized ROC % for the quarter that ended in Dec. 2025 is calculated as:

ROC % (Q: Dec. 2025 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (Q: Dec. 2024 ) + Invested Capital (Q: Dec. 2025 ))/ count )
=-348.195 * ( 1 - 0% )/( (840.283 + 1251.084)/ 2 )
=-348.195/1045.6835
=-33.30 %

where

Invested Capital(Q: Dec. 2024 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=775.083 - 108.61 - ( 129.332 - max(0, 343.999 - 170.189+129.332))
=840.283

Invested Capital(Q: Dec. 2025 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=1424.348 - 132.309 - ( 571.627 - max(0, 579.125 - 620.08+571.627))
=1251.084

Note: The Operating Income data used here is one times the annual (Dec. 2025) data.

2. Joel Greenblatt's definition of Return on Capital:

Vigonvita Life Sciences Co's annualized ROC (Joel Greenblatt) % for the quarter that ended in Dec. 2025 is calculated as:

ROC (Joel Greenblatt) %(Q: Dec. 2025 )
=EBIT/Average of (Net fixed Assets + Net Working Capital)
=EBIT/Average of (Property, Plant and Equipment+Net Working Capital)
     Q: Dec. 2024  Q: Dec. 2025
=EBIT/( ( (Property, Plant and Equipment + Net Working Capital) + (Property, Plant and Equipment + Net Working Capital) )/ count )
=-379.524/( ( (430.699 + max(-127.282, 0)) + (609.81 + max(-166.717, 0)) )/ 2 )
=-379.524/( ( 430.699 + 609.81 )/ 2 )
=-379.524/520.2545
=-72.95 %

where Working Capital is:

Working Capital(Q: Dec. 2024 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(9.307 + 3.509 + 26.737) - (108.61 + 0 + 58.225)
=-127.282

Working Capital(Q: Dec. 2025 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(7.406 + 6.959 + 34.088) - (132.309 + 0 + 82.861)
=-166.717

When net working capital is negative, 0 is used.

Note: The EBIT data used here is one times the annual (Dec. 2025) EBIT data.

3. It is also linked to Joel Greenblatt's definition of Earnings Yield:

Vigonvita Life Sciences Co's Earnings Yield (Joel Greenblatt) % for today is calculated as:

Earnings Yield (Joel Greenblatt) %=EBIT (TTM)/Enterprise Value (Q: Dec. 2025 )
=/14459.157
= %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Vigonvita Life Sciences Co EBIT Related Terms

Vigonvita Life Sciences Co EBIT Historical Data

* Premium members only.

The historical data trend for Vigonvita Life Sciences Co's EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Vigonvita Life Sciences Co EBIT Chart

Vigonvita Life Sciences Co Annual Data
Trend Dec23 Dec24 Dec25
EBIT
14.91 -215.11 -379.52

Vigonvita Life Sciences Co Semi-Annual Data
Dec23 Dec24 Dec25
EBIT 14.91 -215.11 -379.52

HKSE:02630 vs LLY, JNJ, ABBV: EBIT Comparison

For the Drug Manufacturers - General subindustry, Vigonvita Life Sciences Co's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Vigonvita Life Sciences Co EV-to-EBIT vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Vigonvita Life Sciences Co's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Vigonvita Life Sciences Co's EV-to-EBIT falls into.


HKSE:02630
8GF Score
Vigonvita Life Sciences Co Ltd HKSE:02630
EBIT is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Vigonvita Life Sciences Co EBIT Calculation

EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.

For stock reported annually, GuruFocus uses latest annual data as the TTM data. EBIT for the trailing twelve months (TTM) ended in Dec. 2025 was HK$ Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about EBIT →
What does a EBIT of HK$ Mil mean?
Vigonvita Life Sciences Co (HKSE:02630) has a EBIT of HK$ Mil as of Dec. 2025. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on Vigonvita Life Sciences Co.
Is Vigonvita Life Sciences Co's EBIT too high?
Vigonvita Life Sciences Co's current EBIT is HK$ Mil. Overall, Vigonvita Life Sciences Co has a GF Score™ of 8/100, reflecting its overall financial health beyond just this single metric.
How does Vigonvita Life Sciences Co's EBIT compare to LLY and JNJ?
Vigonvita Life Sciences Co's EBIT of HK$ Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBIT for a Drug Manufacturers company?
A good EBIT depends on the Drug Manufacturers industry context. However, EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBIT mean?
A high EBIT can signal that a stock is expensive relative to its fundamentals. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on Vigonvita Life Sciences Co. Vigonvita Life Sciences Co's current EBIT is HK$ Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Vigonvita Life Sciences Co stock overvalued right now?
Vigonvita Life Sciences Co (HKSE:02630) has a current EBIT of HK$ Mil. The current EBIT is HK$ Mil. Vigonvita Life Sciences Co's overall GF Score™ is 8/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBIT calculated?
EBIT is calculated from a company's financial statements. For Vigonvita Life Sciences Co (HKSE:02630), the current EBIT is HK$ Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Vigonvita Life Sciences Co Business Description

Address No. 108, Yuxin Road, 8th Floor, Building A, Suzhou Industrial Park District, Suzhou, CHN, 215123
Vigonvita Life Sciences Co Ltd biopharmaceutical company. It is focused on innovation driven biopharmaceutical development, with a strategic emphasis on addressing unmet clinical needs in the treatment of neuropsychiatric, infectious, and andrological diseases. The company's core Products include LV232, anti-depression drug candidate, VV913: a novel investigational drug candidate for premature ejaculation and, VV116: an oral nucleoside analog with broad-spectrum antiviral potential. The company's operations are located in the PRC and Uzbekistan. Revenue is generated from the out-licensing and the sales of its pharmaceutical products.
8GF Score

Get the complete analysis for HKSE:02630

EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

HK$90.00
Price